US 11,850,244 B2
Drug delivery systems and methods for treatment of bladder dysfunction or disorder using trospium
Dennis Giesing, Lee's Summit, MO (US)
Assigned to TARIS Biomedical LLC, Lexington, MA (US)
Filed by TARIS BIOMEDICAL LLC, Lexington, MA (US)
Filed on Dec. 6, 2019, as Appl. No. 16/706,009.
Application 16/706,009 is a continuation of application No. 14/658,699, filed on Mar. 16, 2015, granted, now 10,500,200.
Application 14/658,699 is a continuation of application No. PCT/US2013/060479, filed on Sep. 18, 2013.
Claims priority of provisional application 61/702,576, filed on Sep. 18, 2012.
Prior Publication US 2020/0108057 A1, Apr. 9, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/46 (2006.01); A61K 9/00 (2006.01); A61M 31/00 (2006.01)
CPC A61K 31/46 (2013.01) [A61K 9/0034 (2013.01); A61M 31/002 (2013.01)] 27 Claims
 
1. A method of reducing bladder spasms and involuntary detrusor contractions in a patient without suppressing overall bladder function, comprising:
locally administering trospium into the bladder of the patient continuously over a treatment period from 30 days to 180 days to achieve a sustained concentration of trospium in urine in the bladder sufficient to produce a therapeutic concentration of trospium in bladder tissue,
wherein the locally administering into the patient's bladder is continuous at a mean average amount of from 0.15 mg/day to 15 mg/day of the trospium for the treatment period.